Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.

A mega deal with Eli Lilly to exclusively market, promote and distribute Emgality (galcanezumab) in China for migraine prevention offers a critical opportunity for C-Bridge backed AffaMed in an untapped, large market, CFO Vijay Karwal told Scrip in an exclusive video interview on the sidelines of EBD's Asia Bio Partnering Forum.

Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.